Boston Scientific drops as 2026 guidance cut outweighs Q1 beat
Boston Scientific shares slid after the company cut its full-year 2026 outlook despite beating Q1 results. Management pointed to pressure in WATCHMAN, faster-than-expected electrophysiology share losses, and weaker urology trends as key headwinds.
1. What’s moving the stock today
Boston Scientific (BSX) is trading sharply lower as investors refocus on the company’s reduced full-year 2026 outlook issued with its first-quarter report. While Q1 results came in solid, the guidance reset has become the dominant catalyst, signaling a slower growth trajectory than the market had been underwriting. (news.bostonscientific.com)
2. The guidance reset: where the cuts landed
Boston Scientific now expects 2026 adjusted EPS of $3.34 to $3.41 and organic revenue growth of 6.5% to 8.0%. Those ranges represent a step down from the company’s prior expectations, and the downgrade has revived concerns that 2026 performance will depend more on execution fixes than on broad-based demand strength. (kwsn.com)
3. What management flagged as the headwinds
Management attributed the outlook cut to three main issues: pressure in the WATCHMAN business, faster-than-expected market share losses in electrophysiology, and weaker-than-expected results in urology. Investors are interpreting that mix as a sign that competitive intensity is rising in core franchises at the same time the company is working through commercial and product-cycle transitions. (fool.com)